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Abstract: Pelvic lymph node dissection (PLND) in patients with bladder cancer varies widely in 
extent, technique employed, and pathological workup of specimens. The present paper provides 
an overview of the existing evidence regarding the effectiveness of PLND and elucidates the 
interactions between patient, surgeon, pathologist, and treating institution as well as their 
cumulative impact on the final postoperative lymph node (LN) staging. Bladder cancer patients 
undergoing radical cystectomy with extended PLND appear to have better oncologic outcomes 
compared to patients undergoing radical cystectomy and limited PLND. Attempts have been made 
to define and assess the quality of PLND according to the number of lymph nodes identified. 
However, lymph node counts depend on multiple factors such as patient characteristics, surgical 
template, pathological workup, and institutional policies; hence, meticulous PLND within a 
defined and uniformly applied extended template appears to be a better assurance of quality 
than absolute lymph node counts. Nevertheless, the prognosis of the patients can be partially 
predicted with findings from the histopathological evaluation of the PLND specimen, such as the 
number of positive lymph nodes, extracapsular extension, and size of the largest LN metastases. 
Therefore, particular prognostic parameters should be addressed within the pathological report 
to guide the urologist in terms of patient counseling.
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Introduction
In the early cystectomy era, the prognosis of patients with lymph node (LN) metastases 
was thought to be uniformly bleak. The value of meticulous LN dissection for patients 
undergoing radical cystectomy (RC) for muscle-invasive bladder cancer was first 
demonstrated in 1982 when Skinner1 showed that cure is possible even in patients with 
LN metastases following RC and concomitant pelvic LN dissection (PLND). In that 
series, PLND provided better local control without adding substantially to morbidity. 
Additionally, postoperative histologic LN staging allowed identification of patients 
at risk who could be directed to adjuvant therapies. Despite this early description, no 
prospective randomized trials have yet been finalized to test this concept. Nevertheless, 
the necessity of PLND within the context of RC is generally accepted, and the majority 
of oncologic urologists perform at least some form of PLND. The present paper provides 
an overview of the existing evidence regarding the effectiveness of PLND and elucidates 
the interactions between patient, surgeon, pathologist, and treating institution, as well 
as their cumulative impact on the final postoperative LN staging.
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Bladder cancer surgery and natural 
course of the disease
Simple cystectomy without PLND was an early surgical 
approach to treating patients with muscle-invasive bladder 
cancer. However, its survival rates were frustrating.2 
Urologists later experimented with expanded dissection 
areas and found that extended dissections were feasible from 
both the technical and perioperative mortality standpoints.3–8 
However, the perioperative mortality could be considerable, 
as illustrated by a case series reported mid-20th century; 
although there were no intraoperative deaths, five of the 22 
patients died within the first 2 postoperative weeks.5
In 1950, Leadbetter and Cooper6 were the first to describe 
the surgical principles of RC before Marshall and Whitmore9 
substantiated the procedure 6 years later. Nowadays, RC 
represents a standard intervention with a 1%–2% rate of 
perioperative deaths in experienced centers.10
Of all patients diagnosed with bladder cancer, 20%– 40% 
initially present with muscle-invasive disease. For those 
undergoing RC with PLND, postoperative tumor stage and 
LN status are important predictors of outcome. The rate of 
LN metastasis is associated with the primary tumor stage, and 
increases from 5%–10% in non-muscle-invasive bladder tumors 
(pT0, pTa, pTis, pT1), to 18% in superficial muscle-invasive 
tumors (pT2a), to 27% in deep muscle-invasive tumors (pT2b), 
and to 45% in extravesical tumors (pT3-4). Accordingly, 
LN-negative pT0, pTa, and pT1 patients have the best outcomes, 
with recurrence-free rates at 5 years and 10 years of .90%.11 
The recurrence-free rates for patients with pT2 pN0-N2 tumors 
are around 75% and 70% at 5 years and 10 years, respectively. 
The rates decrease to 45%–50% at 5 years and 45% at 10 years 
for patients with pT3 pN0-N2 tumors.12 Due to the various sites 
of local invasion, pT4 tumor patients represent a heterogeneous 
cohort with recurrence-free rates around 45% and 35% at 5 
years and 10 years, respectively.11,13,14 In general, progression 
following radical surgery is associated with a dismal prognosis 
and usually occurs within the first 2 years. Overall, survival 
following radical surgery alone remains modest at 43%–57%. 
It is the patient with an organ-confined primary tumor (,pT3) 
and limited LN involvement15 that has the best chance for 
long-term cure. In contrast, patients with intraoperative grossly 
LN-positive disease have even a 25% chance of cure following 
radical surgery with extended PLND.16
Pelvic lymph node dissection – 
ongoing controversies
The main controversy regarding PLND is related to the 
optimal extent of PLND. The fact that the prognostic and 
therapeutic benefits of PLND are based on retrospective 
cohort studies12,17–20 explains the lack of consensus in this 
matter. It is hoped that two ongoing prospective randomized 
trials (the SWOG trial S101121 and the German multicenter 
study LEA22) will soon be able to elucidate this important 
problem and provide the necessary information to define 
a “standard” oncologic template for PLND. The variety 
of PLND templates currently applied makes outcome 
comparisons difficult.
In addition to the template problem, numerous attempts 
have been made to define the proper extent of PLND based 
on the number of LNs identified, and to determine the prog-
nostic value of LN density. These topics will be discussed 
with reference to the inherent connection between patient, 
surgeon, pathologist, and the treating institution.
Pelvic lymph node dissection – 
fundamental considerations
The physiology of lymphatic drainage of the urinary bladder 
is complex. Applying their technetium-based mapping study, 
Roth et al23 identified not fewer than 24 primary lymphatic 
landing sites per urinary bladder. Of these, only 8%–10% 
were detected proximal to the mid-upper third of the common 
iliac vessels. Moreover, no radioactive solitary extra pelvic 
LNs (skip lesions) were identified. Focusing on the small 
pelvis, one-fourth of the primary lymphatic landing sites 
were located in the internal iliac region, with almost half 
(42%) of them lying medial to the internal iliac artery.23 In 
terms of laterality, following strictly unilateral technetium 
injection, at least one primary lymphatic landing site was 
found on the ipsilateral side and 40% of patients had at 
least one additional primary lymphatic landing site on the 
contralateral side.24 This underscores the necessity of bilateral 
PLND in all cystectomy patients.
Prior to the technetium-based analyses, conventional LN 
mapping studies provided important information regarding 
common sites of pelvic LN metastases.25–27 However, these 
studies had considerable limitations, such as overlapping 
dissection areas and the substantial reliance of intraoperative 
labeling on the surgeon’s discretion.
Fundamentally, any analysis of lymphatic tissue based 
on the tissue specimen removed involves an inherent bias; 
it remains unknown how much tissue/how many LNs were 
left behind. As a consequence, the reliable definition of an 
adequate PLND based on postoperative pathologic findings or 
number of LNs removed/identified is not feasible. A possible 
approach would be to develop an imaging technology that can 
identify lymphatic tissue left in situ after RC and PLND.
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The patient
Physiologically, there exist considerable interindividual dif-
ferences in terms of LN counts. Weingärtner et al28 identified 
a mean of 22.7 ± 10.2 pelvic LNs per patient in their autopsy 
series (n = 30) with a wide range of eight to 56 LNs. In another 
recent cadaver study, the range of identified pelvic lymph 
nodes was high (19–53 LNs), even with evaluation by a single 
pathologist.29 In our intra-institutional analysis including onco-
logic outcomes we found a similarly wide range of LNs per 
patient (eight to 55 LNs) without an impact on survival.30,31 
More recently, Mitra et al32 demonstrated that patient charac-
teristics such as age, body mass index, clinical tumor stage, 
type of tumor growth, multifocality, and surgical margins can 
substantially influence total nodal yields.  Therefore, interin-
dividual variation is an important factor affecting the number 
of identified LNs in the context of PLND.
The surgeon
Since the surgeon decides upon the performance, extent, 
and quality of a PLND, he/she may be a key factor for 
 success. Nevertheless, in a Surveillance, Epidemiology, and 
End Results (SEER) program database analysis capturing 
approximately one-fourth of the US population, 40% of all 
patients (n = 1,923) undergoing RC between 1988 and 1998 
did not have a PLND.33 Hollenbeck et al34 demonstrated in 
a similar more resent study (n = 3,603) that the majority of 
cystectomy patients had only a few pelvic LNs (#4 LNs) 
removed at the time of RC, irrespective of hospital volumes. 
In contrast, the rate of patients with $10 LNs decreased from 
35.3%, to 12.7%, to 0% when comparing hospitals with high, 
medium, and low LN counts, respectively. Furthermore, 
high-volume hospitals achieved a more even distribution 
of LN counts.
Without doubt, PLND is performed near to delicate 
anatomic structures and is time consuming. On the other 
hand, a meticulous PLND helps to identify pelvic structures, 
facilitates cystectomy, and offers better vascular control35 
without increasing perioperative morbidity.27,36 It is difficult 
to estimate the impact of surgical education/experience, insti-
tutional philosophy, and possible economic considerations 
(reimbursement) on the extent and thoroughness of PLND. 
Nevertheless, these factors may explain, to some extent, the 
differences in practice among urologists.
A critical issue for the surgeon is whether to adopt a 
new surgical approach, eg, whether to switch from open to 
minimally invasive RC. While it has been shown that even 
a super-extended PLND is feasible and safe with robotic 
assistance,37 PLND is often omitted in the initial phase of 
the procedural learning curve.38 The performance of an 
extended PLND is significantly associated with institutional 
and individual surgeons’ case number and surgical volume.9 
However, urothelial cancer does not allow any oncologic 
compromise and requires a thorough extended PLND, 
irrespective of surgical approach.
The pathologist
Because pathology findings are greatly impacted by the 
specific local tissue workup process, several factors have 
to be considered when comparing pathology reports on LN 
specimens from various institutions.39 First, the submission of 
specimens in separate packets instead of en bloc significantly 
increases the number of reported LNs.40 The use of smaller 
specimens might facilitate macroscopic identification of LNs 
by the pathologist and may also allow for better fixation and 
processing,41 thus improving the detection of LNs. Second, 
the use of certain fixation and processing methods, eg, 
acetone or Carnoy’s solution, results in resolution of fatty 
tissue and enhances the macroscopic visibility of LNs,42 
facilitating identification of LNs and potentially increasing 
nodal counts. Third, the more meticulous the pathologist’s 
examination of the specimens, the greater the number of 
LNs identified. Moreover, the more accurate the pathologist’s 
report on the embedding of nodes, the easier the counting of 
LNs under the microscope (Figure 1).43 Fourth, and a rarely 
reported factor, the amount of tissue that is embedded for 
microscopic examination affects LN yield; embedding the 
entire specimen, for example, increases the number of nodes 
identified.42 According to personal, unpublished data (2009), 
B
4 mm
A
4 mm 
Figure 1 Images of two histopathological lymph node slides.
Notes: (A) Described macroscopically as containing four embedded lymph nodes, 
(B) and containing one sliced lymph node. This information made the lymph node 
counting both easier and more accurate.
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approximately two additional nodes are found per packet in the 
remaining, not routinely embedded lymphadenectomy tissue. 
Fifth, although the histological criteria defining LNs are clearly 
established, the determination of a LN in a microscopic slide 
not only depends on the sectional plane through the LN, but 
also varies between pathological institutes and pathologists.43 
Parkash et al43 evaluated LN counts on slide scans performed 
by ten pathologists, each pathologist receiving the same series 
of slides for review. They noted considerable interobserver and 
intra-observer variability, which was particularly dependent 
on the macroscopic description of the slide given by the study 
coordinator.
Finally, molecular staging techniques, such as reverse 
transcription real-time quantitative PCR (RT-qPCR), 
have been investigated to determine whether they can detect 
the presence of missed micrometastases in LNs during 
routine pathological workup. RT-qPCR has been applied in 
breast,44 colon,45 and urinary bladder cancers46,47 to detect 
small changes in gene expression (eg, CK-19, CK10, or 
Uroplakin II) indicative of micrometastases or disseminated 
cancer cells. In line with findings on other neoplasias, the 
detection of micrometastases in bladder cancer is increased 
by RT-qPCR,46,47 and is linked to unfavorable tumor char-
acteristics47 and even associated with adverse outcomes.46 
However, in bladder cancer, the true clinical impact of 
these molecular micrometastases remains largely unknown 
and external validation of these data is urgently needed. 
 Therefore, these techniques are not routinely used.
Another evaluated molecular technique is keratin immu-
nohistochemistry (keratin IHC). In breast cancer, keratin IHC 
appears to increase the detection of occult micrometastases, 
particularly in sentinel LNs.48 However, the sentinel LN 
hypothesis is not a reliable concept in bladder cancer patients 
due to the high rate of false negative nodes.49 Furthermore, it 
has been shown that keratin IHC does not detect additional 
micrometastases within a complete lymphadenectomy 
 specimen.50 As a consequence, investigation of keratin IHC 
is no longer being investigated.
In bladder cancer patients, neoadjuvant chemotherapy 
significantly improves survival,51,52 which in future might 
shift the paradigm towards a routinely administered 
neoadjuvant chemotherapy.53 The challenge for the 
pathologist will then be to define prognostic and predictive 
features in medically pretreated surgical specimens. The 
number of evaluated lymph nodes in lymphadenectomy 
specimens after neoadjuvant chemotherapy seems to 
be virtually the same compared to treatment naïve 
specimens.54 However, as in rectal55,56 and esophageal57–59 
cancers, tumor regression grades, which are thought to 
quantify the histopathological extent of tumor response 
to chemotherapy, have shown stronger prognostic impact 
in bladder cancers than the classification of malignant 
tumors (yTNM) stages.54 Consequently, pathologists should 
start to report and urologists should become accustomed 
to these pathologic alterations in order to better interpret 
patient outcomes.
The treating institution
With increasing numbers of RCs performed using robotic 
assistance, interesting data are emerging regarding the impact 
of surgical experience on the performance of PLND. The 
International Robotic Cystectomy Consortium has dem-
onstrated that the performance, extent, and thoroughness 
of robotic-assisted surgery are affected by both individual 
surgical volumes and institutional case volumes.9
Additionally, it is not solely the surgeon’s personal 
experience and preference, but also the institutional 
philosophy that decide on the choice of template applied 
at RC. The surgical template impacts patient outcome, as 
demonstrated in two consecutive observational studies12,17 
evaluating three differing PLND templates from three 
cystectomy centers. Dhar et al17 compared the oncologic 
outcomes of patients undergoing RC with limited PLND to 
that of patients undergoing RC with extended PLND. With 
an extended PLND up to the mid-upper third of the common 
iliac vessels instead of a limited PLND only, the rate of 
LN-positive patients doubled. This indicates the substantial 
under-staging of patients undergoing limited PLND. 
Furthermore, the application of extended PLND resulted 
in a significantly better 5-year recurrence-free survival, 
irrespective of the final pathologic LN status. The removal 
of all lymphatic tissue up to the inferior mesenteric artery 
does not confer an additional survival benefit, as shown with 
the subsequent template comparison.12
Fang et al60 demonstrated the effect of a policy requiring 
identification of a minimum number of LNs. According to 
this policy, any lymphadenectomy specimen with fewer than 
16 LNs was resubmitted to a senior pathologist for review. 
As a consequence, the median number of LNs identified per 
patient increased by five, and the rate of specimens with more 
than 16 LNs almost doubled from 43% to 70%.
Postoperative lymph node staging
Despite improved imaging technology, PLND remains 
the most accurate and reliable approach to staging LNs in 
bladder cancer patients. Different parameters have been 
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investigated in lymphadenectomy specimens in terms 
of their prognostic value, such as number of identified 
and positive LNs, LN density, the diameter of the 
largest metastasis, and the extracapsular extension of LN 
metastases.
Multicenter61–63 and single institution studies18,20 have 
shown that a higher number of identified LNs can be 
associated with better outcomes. However, as discussed 
above, the number of LNs varies substantially between 
institutions. This must be taken into account when numbers 
of identified LNs are evaluated in terms of a generally 
applicable prognostic tool. If, in single institution series, 
the outcomes of patients analyzed according to interquartile 
LN ranges is virtually identical, variations of LN counts 
might depend more on individual physiological variations 
and procedural (histological workup) differences and could 
reflect the uniformity of the lymphadenectomy performed 
in this cohort.30 Thus, analysis of interquartile ranges of 
LN counts for survival might serve as an institutional 
quality control for lymphadenectomy. As such, total LN 
yield is a problematic measure of dissection extent or 
oncologic quality. This was demonstrated by Dorin et al,64 
who compared LN counts between two cystectomy centers, 
applying the same PLND template. Despite differing median 
LN counts (40 versus 72 LNs), neither the proportion of 
LN-positive patients nor the oncologic outcomes of the two 
cohorts were found to be different. The authors concluded 
that the applied PLND template is more important than 
total LN yield.
Different investigators have proposed LN density (ratio 
of positive and identified nodes) as a prognosticator of 
survival.15,65,66 In various series,15,65,66 LN density predicted 
survival in univariate analyses. In contrast, multivariable 
confirmation was only achieved in few studies.15 LN 
density is not only a function of nodal tumor burden and 
extent or quality of lymphadenectomy, but also of the 
natural variation in the number of pelvic LNs and differ-
ences in pathological workup. Therefore, this concept is of 
questionable value. Similar to total LN yield, LN density 
depends substantially on institutional standards. Hence, 
categorical LN densities used to risk stratify patients 
for counseling regarding prognosis may be useful on an 
institutional level,67 but any interinstitutional comparison 
will be difficult.
The size of the largest LN metastasis is a prognostic factor 
in different cancers68–70 and, according to the 7th TNM clas-
sification, determines postoperative LN (pN) stages in head 
and neck, as well as in gynecological cancers.71 In bladder 
cancer, however, the diameter of the largest LN metastasis is 
not an independent risk factor and therefore is not included 
in the current 7th TNM classification.
The prognostic relevance of extracapsular extension 
(ECE) in patients with LN metastases (Figure 2) has 
been evaluated in five single center cohorts30,72–76 and 
one multicenter analysis77 with divergent results. ECE 
was the strongest independent adverse risk factor in our 
own cohort.30,75 Poor outcomes of patients with ECE was 
also noted in other series.72–74,76 However, in the study of 
Frank et al,72 ECE was found not to be an independent risk 
factor in patients after limited PLND, while the study of 
Jeong et al73 reported a low frequency of ECE. Conversely, 
ECE was not a prognosticator in the MD Anderson cohort,74 
but the information on ECE was based on pathology records 
instead of a slide review. Similarly, Stephenson et al76 could 
not detect a prognostic impact. Finally, ECE was identified 
as an independent unfavorable parameter for cancer 
recurrence and death in a recently published multicenter 
retrospective study.77 Unfortunately, in that study, PLND was 
not uniformly performed and a central pathologic review of 
all slides was not performed. Taken together, the substantial 
differences between cohorts and methods existing between 
the aforementioned studies might have contributed to the 
conflicting results.
Lymphovascular invasion (LVI) is another prognostic 
factor in the assessment of bladder cancer. LVI is particu-
larly investigated in cystectomy and transurethral resection 
specimens of primary tumors,78,79 and only Fritsche et al80 
evaluated the prognostic impact of perinodal LVI in PLND 
specimens. Although the latter multicenter study lacks a 
Figure 2 Extracapsular extension of lymph node metastases.
Notes: Lymph node metastasis of urothelial bladder cancer perforating the lymph 
node capsules and extending to the perinodal soft tissue.
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complete pathological review, perinodal LVI was found to 
be an independent risk factor for early cancer-related death. 
Therefore, this parameter should be routinely reported in the 
final pathological report.
Conclusion
The optimal extent of PLND in bladder cancer is still under 
debate. Based on the present analysis of retrospective cohort 
studies, meticulous extended PLND to the mid-upper third 
of the common iliac vessels should be the standard of care 
for patients with high risk non-muscle-invasive and muscle-
invasive bladder cancer. By reporting the number of LNs iden-
tified, we outline the lymphatic tissue that has been  removed; 
however, the lymphatic tissue that has been left behind may 
be responsible for cancer recurrence and remains unquanti-
fied. Moreover, LN counts depend on multiple factors such as 
patient, surgeon, pathologist, and institution, and consequently 
are not the best markers of the quality of a PLND. Neverthe-
less, some histopathological parameters resulting from the 
pathological workup help to better predict patient outcomes.
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